The Biomarkers Associated With Myocardial Infarction

Suaad Abaas Lafta [1], Awatif Hameed Issa *[2], Mazin Abed Hazza[3], Alaa Hussein Abed[4]

[1,2]University of Basrah- college of science/Iraq
[3]University of Basrah- college of medicine/Iraq
[4] Basrah for science and technology private university college /Iraq
Corresponding Author: awatifhissa@uobasrah.edu.iq

ABSTRACT

Introduction: Myocardial infarction (MI) is a major cause of morbidity and mortality worldwide. It is caused by a blockage of a coronary artery due to the accumulation of fat within its inner surface (atherosclerosis). Early diagnosis of MI has an important role in assisting clinicians in prompt planning for its treatment and thus reducing the number of its deaths. There are many biomarkers that used in the diagnosis of MI, especially in the first hours of chest pain attack. Cardiac enzymes, as cTnI, H-FABP, MYO, and CK-MB are released after heart muscle injury due to insufficient blood supply. In the past, it was based solely on the theory of lipids role in the etiology of atherosclerosis. Currently, inflammation has been stated to play an essential role in developing atherosclerosis. Monocytes, macrophages, lymphocytes and smooth muscle cells accumulates release many cytokines or inflammatory biomarkers. Therefore, many studies have emerged seeking to investigate the use of anti-inflammatory drugs to reduce the progression of the atherosclerosis process. The aim of the present study was to investigate the association of cardiac and inflammatory biomarkers to myocardial infarction and the correlation between inflammatory markers (CRP, Hs-CRP, IL-6 and PCT) and cardiac markers in MI patients.
Patients and Method: The present study included 20 MI patients and 20 healthy individuals (controls). In all the cases and controls, levels of cardiac and inflammatory biomarkers were measured by special kits from Hotgen company via phosphorous technology using UPT-3A converting phosphor immunological analyzer.
Results: The levels of both cardiac and inflammatory biomarkers were significantly increased in MI cases as compared to controls. Also, there was significant positive correlation between cardiac and inflammatory biomarkers in MI cases.
Conclusions: The positive correlation between cardiac and inflammatory biomarkers in MI indicates that inflammation occurs in myocardial infarction. Hence it is concluded that inflammatory biomarkers (CRP, Hs-CRP, IL-6 and PCT) can be markers of MI and can be used for diagnostic purposes in patients.

INTRODUCTION

Cardiovascular disease is the leading cause of death worldwide. The number of cardiovascular deaths is higher than cancer deaths and more than any other cause of death (AHA, 2019). The deaths reach up to 17.9million annually, which is equal to 31% of all deaths (Wierer *et al.,*2018). In Iraq, the mortality rate due to cardiovascular diseases is about 33% of all deaths (Turk *et al.,* 2018). Myocardial infarction is a type of coronary heart disease (CHD), that results from rupture of an arterial sclerosis plaque and a thrombus that works to block the coronary artery, which supply the heart, causing necrosis and death of part of the heart muscle (Shi *et al.*, 2016; Rathore *et al.,*2017). Internationally, it was reported that at least one American develops myocardial infarction approximately every 40 minutes (AHA, 2019). In the past, it was based solely on the theory of lipids role in the etiology of atherosclerosis. Currently, inflammation has been stated to play an essential role in developing atherosclerosis. Monocytes, macrophages, lymphocytes and smooth muscle cells accumulates release many cytokines or inflammatory biomarkers (Beverly and Budoff, 2019) The underlying cause of a heart attack due to MI is atherosclerotic, which is caused by the development of layers of fatty deposits on the inner walls of the arteries (Amirfakhryan, 2019). The development of these deposits leads to narrowing and gradual blockage of blood flow in the artery. It is a long-term disease that progresses slowly (Lacy *et al.,* 2019).
Atherosclerosis is a chronic pathology of multiple modifiable risk factors (diabetes, hypertension, obesity, sedentary life, emotional stress, unhealthy food habit, smoking, and alcohol consumption) and non-modifiable factors (age, gender, race, and family history). It has been stated that chronic inflammation has a role in increasing the risk of cardiovascular disease, especially psoriatic arthritis and rheumatoid arthritis (Groh *et al.,* 2018). Moreover, the statement of bacterial and viral infections participation in the process of atherosclerosis development, justifies mentioning that targeting infections with antibiotics can be promising as being a part of a protocol option to reduce atherosclerosis (Ridker *et al.,*2020; Moriya, 2019).
Measuring biomarkers levels in the patient's serum is a method for decision-making and can predict the severity of atherosclerosis (Martinez *et al.,* 2020).
Cardiac troponin I (cTnI) is an extremely sensitive biomarker in diagnosing and determining the severity of coronary heart disease, and highly specific in excluding the disease. It gives more predictive values than the stress ECG (Aydin *et al.*, 2019; Anwar *et al.*, 2016).
Creatine kinase –Myocardial Band (CK-MB) is an enzyme found in the heart muscle, which is an important biomarker for the diagnosis of myocardial infarction. It is more specific than other heart enzymes and considered the golden standard for diagnosing myocardial infarction. (Mytili and Malathi, 2015; Aydin *et al.,* 2019; Anwar *et al.,* 2016).
D-dime is a promising and important vital indicator for identifying blood clots, which molecules result from the breakdown of fibrin in the blood vessels (Zhang *et al.,* 2019).

N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a diagnostic marker for detecting heart failure (Eriksson et al., 2019; Pan et al., 2017).

C-reactive protein (CRP) is a biomarker secreted by the liver after being stimulated by cytokines in cases of infections, and can be used to assess the risk of cardiovascular disease; however, it has a low specificity (Zhu et al., 2018).

High sensitivity-CRP (Hs-CRP) is a technique developed to detect very low levels of CRP to more accurately determine the existence of the inflammation process compared to CRP (Pelusoet al., 2019).

Procalcitonin (PCT) hormone is a peptide consists of 116 amino acids with low molecular weight, approximately 13 kDa (Ichihara *et al.,*2016) (Jiao *et al.,*2015). The proportion of the hormone is 0.033 ng/ml and rises to 5000 ng/ml in cases of bacterial infection only, but it does not rise in viral infections (Bradford, 2019).

Interlukine-6 (IL-6) is a type of cytokines, which has hormone-like properties. It has anti-inflammatory properties, has a role in innate and adaptive immunity, causes fever during infection, and is secreted by monocytes, macrophage devoured in response to other cytokines such as IL-11, TNF. Its function is to regulate acute phase proteins and chronic infections, and its levels increase in patients with vascular diseases compared to healthy people (Yu *et al*., 2017; Nassem *et al*., 2016).

PATIENTS AND METHOD

Out of a total of 20 patients, 5 (25%) were females and 15 (75%) males, with a mean age of 55.25± 12.53 (range of 35-80) years, participated in this study. All patients were diagnosed as having MI. A total of 20 healthy individuals enrolled in this study as a control group; their age and gender were matched with the patients group. Cancer and hepatitis patients were excluded from this study. Data were collected from the cardiac center in Al-Sadr Teaching Hospital via specially structured questionnaire. This included sociodemographic and health data. The study took place during the period from 13 October 2019 to 27 October 2020.

Venous blood was collected from patients and controls in EDTA, sodium citrate and gel tube. Centrifugation processes were being done to obtain serum and plasma by Rotofix 32 A at a speed of 3000 cycles per minute for 10 minutes. Then cardiac and inflammatory biomarker testes were done numbers and averages, and quantitative variables are expressed as a mean± SD. A comparison by special kits from Hotgen company via phosphorous technology using UPT-3A converting phosphor immunological analyzer.

All statistical analyzes were performed using Statistical Package of Social Sciences (SPSS) version 23. Categorical variables are expressed as percentages, was made between patients and the control groups using chi-square test or Fisher's exact test qualitative variables, and Mann-Whitney test for quantitative nonparametric variables. Spearman's test was used to find the correlation between the nonparametric quantitative variables. The level of significance was set at (P < 0.05).

RESULTS

A total of 40 individuals were included in this study. Of those, 20 were cases of MI and 20 were controls. Table (1) shows the levels of cardiac and inflammatory markers in cases and controls. The levels of these markers were statistically significantly (p<0.05) increased in MI cases as compared to controls.

Table (2) and figure (1) show the correlation between cardiac and inflammatory markers in MI cases. Positive correlations were found between cardiac and inflammatory markers in MI cases.

Serum CRP levels were found to be strongly positively correlated with CK-MB, H-FABP, MYO and cTnI (r=0.682, 0.653, 0.613 and 0.566, respectively, in a significance level of p<0.01).

A strong positive correlation was found between serum PCT levels with NT-proBNP, MYO and H-FABP (r= 0.644, 0.567 and 0.501 respectively, in a significance level of p<0.01) in MI patients.

On the other hand, we found medium significant correlations of Serum CRP levels with D-dimer and NT-proBNP (r= 0.478, 0.41 respectively, both p<0.013); Hs-CRP with NT-proBNP (r=0.455); PCT with (cTnI, CK-MB and D-dimer), and IL-6 with (cTnI, H-FABP, NT-proBNP, CK-MB and D-dimer).

Finally, a small correlation of IL-6 with MYO (r=0.284).

Table (1): The differences in the levels of cardiac and inflammatory biomarkers in MI cases and controls.

Biomarker	MI N (%)	Control N (%)	P-Value
IL-6 (pg/ml)			
<7	6 (30%)	16 (80%)	0.001
≥7	14 (70%)	4 (20%)	
CRP (mg/L)			
<8	6 (30%)	19 (95%)	0.0001
≥8	14 (70%)	1 (5%)	
hs-CRP (mg/L)			
<1	0 (0%)	12 (60%)	0.0001
≥1	20 (100%)	8 (40%)	
PCT(ng/ml)			
<0.5	9 (45%)	20 (100%)	0.0001
≥0.5	11 (55%)	0 (0%)	
H-FABP (ng/ml)			0.0001
<7	5 (25%)	20 (100%)	

≥ 7	15 (75%)	0 (0%)	
MYO (ng/ml)			
<48	11 (55%)	20 (100%)	0.001
≥ 48	9 (45%)	0 (0%)	
cTnI (ng/ml)			
<0.5	4 (20%)	20 (100%)	0.0001
≥ 0.5	16 (80%)	0 (0%)	
CK-MB (ng/ml)			
<4.99	0 (0%)	20 (100%)	0.0001
≥4.99	20 (100%)	0 (0%)	
NT-proBNP (pg/ml)			
<450 (age≤750) <900 (age≥75)	7 (35%)	20 (100%)	0.0001
≥ 450 (age≤75) ≥900 (age≥75)	13 (65%)	0 (0%)	
D-dimer (ng/ml)			
<500	8 (40%)	19 (95%)	0.0001
≥500	12 (60%)	1 (5%)	

6

Table (2): The correlation coefficient, r-values, between cardiac and inflammatory biomarkers in patients of MI

Inflammatory biomarkers	Cardiac biomarkers					
	H-FABP	**MYO**	**cTnI**	**CK-MB**	**NT-proBNP**	**D-dimer**
IL-6	0.384*	0.248	0.379*	0.331*	0.402*	0.404*
CRP	0.653**	0.613**	0.566**	0.682**	0.413**	0.478**
HS-CRP	0.662**	0.596**	0.593**	0.767**	0.455**	0.548**
PCT	0.501**	0.567**	0.452**	0.418**	0.644**	0.431**

* significant ($p < 0.05$)
** highly significant ($p < 0.01$)

Figure (1): The correlation between CRP and cardiac biomarkers in MI cases and control groups.

Figure (2): The correlation between Hs-CRP and cardiac biomarkers in MI cases and control groups.

Figure (3): The correlation between PCT and cardiac biomarkers in MI cases and control groups.

Figure (4): The correlation between IL-6 and cardiac biomarkers in MI cases and control groups.

DISCUSSION

In the present study, the association of cardiac markers (cTnI, H-FABP, MYO, CK-MB, NT-proBNP and D-dimer) and inflammatory markers (CRP, Hs-CRP, IL-6 and PCT) with MI was assessed and the correlation between the two types of markers was tested.

We found significantly increased levels of all cardiac and inflammatory biomarkers in MI cases compared to controls (p<0.05), which is mostly consistent with the results of several previous studies that documented a role for inflammation in the development of atherosclerosis. Moreover, we found significant correlations between the markers from the two groups.

Cardiac Markers:

H-FABP is mainly found in the heart muscle; and in case of heart muscle cells, it is released early to the blood. An elevated level of H-FABP can be tested in 30 minutes after the injury, reaches its peak in up to 8 hours and decreases to its original level after 24 hours (Mytili and Malathi, 2015). This goes with the finding of the current study, which found that it is extremely significantly statistically associated with MI when compared to control individuals. Rathore *et al.,* (2017) in their study observed significant higher mean levels of cardiac markers MYO activity in AMI cases when compared to that of controls, which agrees the results of this study. Again it is one of the early elevated markers in the blood after the onset of injury to the heart muscle, reaches its peak in up to 12 hours and declines to its original level very shortly. However, it lacks specificity to the heart tissue. That is why its level is recommended to be tested in conjunction with the cTnI or CK-MB (Mytili and Malathi, 2015).

Singh *et al.,* (2016) concluded that a combination of cTnI activity was sufficient for the early diagnosis of acute myocardial infarction (AMI). It is specific for the myocardium, which has made it an excellent cardiac marker of injury.

It starts to increase in up to 8 hours post heart muscle injury, (Mytili and Malathi, 2015). It is a highly sensitive test for diagnosing and predicting coronary artery disease and plays a considerable role in the process of risk stratification (Tibaut *et al.*, 2019). These facts can explain the results of our study, when it was found to be extremely associated to MI.

Rathore *et al.,* (2017) documented higher levels of CK-MB in AMI patients when compared to controls, which agrees the results of this study. It is not measured as a single diagnostic indicator, but in conjunction with the troponins or MYO (Mytili and Malathi, 2015). Although,

previously, the total CK was used to assess myocardial infarction. Mytili and Malathi, (2015) and Singh *et al., (2002)* concluded that a CK-MB activity can be sufficient for the early diagnosis of acute myocardial infarction (AMI).

Eriksson *et al.,* (2019) stated that NT-proBNP has a prognostic value in patients with heart failure. Although, NT-proBNP was found to be significantly associated with MI, and previous research has shown that its elevation can be a predictive marker of death and heart failure, it was stated that it cannot be used for the diagnosis of AMI (Mytili and Malathi, 2015).

D-dimer was shown to be associated with the extent of coronary heart disease, which agrees the results of this study, but it has a low specificity; therefore, all other fibrinolysis conditions should be excluded when used as a risk marker for atherosclerosis (Tibaut *et al.,* 2019).

Inflammatory Markers

IL-6 has a major role in the recruitment and activation of inflammatory cells in response to ischemia (Mytili and Malathi, 2015). Wennberg *et al.,* (2012) documented an association between IL-6 and MI risks; and Filardo *et al.*, (2015) reported that seropositivity of IL-6 may be predictive of atherosclerotic cardiovascular risk.

Furthermore, it is considered as one of the important tools for assessing the risk of coronary atherosclerosis, which supports the results of this study (Ridker *et al*, 2020).

(Sesani *et al.,* 2016) and (Rathore *et al*., 2017), who mention that CRP is the most frequent marker of inflammation, which its relation to MI has been studied extensively in recent years. In agreement with the present study findings, Wennberg *et al., (2012)* documented an association of inflammatory markers, such as CRP, with MI risks. Moreover, it was stated that these markers are of considerable importance in the pathophysiology of the disease. Ahmed et al., *(2017)* mentioned in their study that it is of benefit to measure serum levels of PCT and CRP in diagnosing cardiovascular complications in type 2 diabetic patients. Our study results agree the results of Baruah *et al.*, (*2012*) in their study showed that the role and importance of the CRP, contributes to provide a predictive value in the diagnosis of AMI. Also, it sensitivity and specificity (Mytili and Malathi, 2015).

When Hs-CRP is considered, it has been documented that screening techniques have been developed, to detect it, are used to assess heart disease risk associated with infections (Limijadi, *et al*., 2020). Recent studies have also

demonstrated the ability of HS-CRP to predict the presence of atherosclerotic plaques and it is an important tool that can help physicians in putting immediate treatment plans (Ammirati *et al.*, 2015; Macfadyen *et al.*, 2017), as it was found that it has a major role in improving the risk stratification of CAD (Chong *et al.,* 2020; Fonseca and Izar, 2016; Koenig, 2013). The mechanism has been stated to link high serum Hs-CRP levels to the process of inflammation of the myocardium and higher levels of Hs-CRP are correlated with the severity of the inflammation of the injured myocardium (Yao, H. C. *et al*, 2013). In addition, Filardo *et al.*, (2015) reported that seropositivity of HS-CRP may be predictive of atherosclerotic cardiovascular risk.

All the above support the results of our study, when we found that Hs-CRP is associated with MI and is positively correlated to the cardiac biomarkers.

This study results agreed the results of (Kafkas *et al.*, 2008) who documented that PCT was significantly associated with MI. Moreover, (ENTürk *et al.*, 2007) and (Özbay *et al.*, 2020) who recommended its use in assessing the prognosis and severity of coronary artery disease.

LIMITATIONS

Researchers find it is crucial to point out the following limitations of the study, without which, the results would be better conclusive:

1. The time of taking blood samples to be tested was variable among patients and lied between 5 -12 hours after being admitted to the coronary care unit in the hospital. This was a bit wide range for the levels of markers tested. That is to say, the levels among patients do not represent close/similar time period after the MI attack. However, in spite of this, the differences among markers levels were statistically extremely significant, and the wide variability in post attack period could no mask the significance.
2. The results based on a single center only, which could lead to selection bias.
3. The sample size was too small to produce conclusive results. That was because of the restriction imposed due to the outbreak of COVID-19. However, the result was not different from other studies worldwide.

CONCLUSIONS

The current results found increased levels of inflammatory markers (CRP, HS-CRP, IL-6 and PCT) along with cardiac markers (cTnI, H-FABP, MYO, CK-MB, NT-proBNP and D-dimer) and significant positive correlations among the markers of the two groups in MI patients. It indicates that there was significant inflammatory process associated with myocardial infarction.

REFERENCES

1. AHMED, H. H., SHOUSHA, W. G., EL-MEZAYEN, H. A., EMARA, I. A., & HASSAN, M. E. (2017). Clinical significance of procalcitonin and c-reactive protein in the prediction of cardiovascular complications in patients with Type 2 diabetes mellitus. Asian J Pharm Clin Res, 10(9), 297-306.
2. American Heart Association. Heart Disease and Stroke Statistics—2019 at a Glance. (2019).
3. Ammirati, E., Moroni, F., Norata, G. D., Magnoni, M., & Camici, P. G. (2015). Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. Mediators of Inflammation, 2015.
4. Amirfakhryan, H. (2019). Vaccination against atherosclerosis: An overview. Hellenic Journal of Cardiology.
5. Anwar, A. W. A. I. S., Khan, H. A., Hafeez, S. A. M. R. A., and Firdous, K. (2016). A comparative study of creatine kinase-MB and Troponin levels among diabetic and non-diabetic patients with acute MI. Pak J Med Health Sci, 10, 296-298.
6. Aydin, S., Ugur, K., Aydin, S., Sahin, İ., and Yardim, M. (2019). Biomarkers in acute myocardial infarction: current perspectives. Vascular health and risk management, 15, 1.
7. Baruah, M., Nath, C. K., Chaudhury, B., Devi, R., & Ivvala, A. S. (2012). A study of serum uric acid and C-reactive protein in acute myocardial infarction. International Journal of Basic Medical Sciences and Pharmacy (IJBMSP), 2(1).
8. Beverly, J. K., and Budoff, M. J. (2019). Atherosclerosis: Pathophysiology of insulin resistance, hyperglycemia, hyperlipidemia, and inflammation.
9. Bradford, D. J. (2019). The Development of a Medical Biomarker Test to Aid in Rapid Screening for the Presence of Infectious Diseases.
10. Chong, Y., Ren, Q., Li, Y., Li, C., Feng, F., & Zhou, Y. (2020). Biomarkers for Prediction of Cardiovascular Events in Community-Dwelling Adults Aged 40 or Older. International Heart Journal, 19-240.
11. ENTürk, T., Cordan, J., Baran, I., Özdemir, B., Güllülü, S., Aydinlar, A., & GÖral, G. (2007). Procalcitonin in patients with acute coronary syndrome: correlation with high-sensitive C-reactive protein, prognosis and severity of coronary artery disease. Acta cardiologica, 62(2), 135-141.
12. Filardo, S., Di Pietro, M., Farcomeni, A., Schiavoni, G., & Sessa, R. (2015). Chlamydia pneumonia-mediated inflammation in atherosclerosis: a meta-analysis. Mediators of inflammation, 2015.
13. Eriksson, B., Wändell, P., Dahlström, U., Näsman, P., Lund, L. H., and Edner, M. (2019). Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register. Scandinavian journal of primary health care, 37 (4), 434-443.
14. Fonseca, F. A. H., & Izar, M. C. D. O. (2016). High-sensitivity C-reactive protein and cardiovascular disease across countries and ethnicities. Clinics, 71(4), 235-242.
15. Groh, L., Keating, S. T., Joosten, L. A., Netea, M. G., and Riksen, N. P. (2018, February). Monocyte and macrophage immunometabolism in atherosclerosis. In Seminars in immunopathology (Vol. 40, No. 2, pp. 203-214). Springer Berlin Heidelberg.
16. Ichihara, K., Tanaka, T., Takahashi, S., Matsukawa, M., Yanase, M., Kitamura, H., and Masumori, N.(2016). Serum procalcitonin level in chronic hemodialytic patients with no evidence of bacterial infection. Renal Replacement Therapy, 2 (1), 9.
17. Jiao, J., Wang, M., Zhang, J., Shen, K., Liao, X., and Zhou, X. (2015). Procalcitonin as a diagnostic marker of ventilator- associated pneumonia in

cardiac surgery patients. Experimental and therapeutic medicine, 9 (3), 1051-1057.

18. Kafkas, N., Venetsanou, K., Patsilinakos, S., Voudris, V., Antonatos, D., Kelesidis, K., ... & Cokkinos, D. V. (2008). Procalcitonin in acute myocardial infarction. Acute cardiac care, 10(1), 30-36.

19. Koenig, W. (2013). High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. International journal of cardiology, 168(6), 5126-5134.

20. Lacy, M., Atzler, D., Liu, R., de Winther, M., Weber, C., and Lutgens, E. (2019). Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis. Pharmacology and therapeutics, 193, 50-62.

21. Limijadi, E. K. S., Ariosta, B. R., Utami, S. B., and Sofia, S. N (2020). Relationship between Inflammation Markers and Stenosis Degrees in Stable Coronary Heart Disease.

22. Macfadyen, J. G., Chang, W. H., Ballantyne, C., ... & Kastelein, J. J. (2017). Antiinflammatory therapy with canakinumab for atheroRidker, P. M., Everett, B. M., Thuren, T., sclerotic disease. New England journal of medicine, 377(12), 1119-1131.

23. Martinez, E., Martorell, J., and Riambau, V. (2020). Review of serum biomarkers in carotid atherosclerosis. *Journal of Vascular Surgery*, *71* (1), 329-341.

24. Moriya, J. (2019). Critical roles of inflammation in atherosclerosis. Journal of cardiology, 73 (1), 22-27.

25. Mythili, S., and Malathi, N. (2015). Diagnostic markers of acute myocardial infarction. Biomedical reports, 3 (6), 743-748.

26. Naseem, S., Iqbal, R., and Munir, T. (2016). Role of Interleukin-6 in Immunity: A Review. International Journal of Life Sciences Research, 4 (2), 268–274.

27. Özbay, S., Coskun, A., & Eren, S. H. (2020). Can Platelet/Mean Platelet Volume ratio, Neutrophil/lymphocyte ratio, and Procalcitonin used for Predicting Prognosis in Acute Coronary Syndrome? Journal of Anesthesiology and Pain Therapy, 1(1).

28. Pan, Y., Li, D., Ma, J., Shan, L., and Wei, M. (2017). NT-proBNP test with improved accuracy for the diagnosis of chronic heart failure. Medicine, 96 (51).

29. Peluso, R., Caso, F., Tasso, M., Sabbatino, V., Lupoli, R., Di Minno, M. N. D., ... and Scarpa, R. (2019). Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis. Open access rheumatology: research and reviews, 11, 143.

30. Rathore, V., Singh, N., Rastogi, P., and Mahat, R. K. (2017). Correlation of Inflammatory Marker with Glycogen Phosphorylase BB (GPBB) in Patients of Acute Myocardial Infarction.

31. Rathore, V., Rastogi, P., Chandel, Y. S., Singh, N., & Mahat, R. K. (2017). Comparative status of glycogen phosphorylase BB, myoglobin, and CK-MB for early diagnosis of acute myocardial infarction. *International Journal of Medical Science and Public Health*, *6*(7), 1158-1163.

32. Ridker, P. M., MacFadyen, J. G., Glynn, R. J., Bradwin, G., Hasan, A. A., and Rifai, N. (2020). Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. European Heart Journal.

33. Sesani, S., Vijayabhaskar, M., Madhulatha, M. L., & Lokary, V. (2016). Assessment of C-reactive protein in cases of acute myocardial infarction and its correlation with risk factors. *INTERNATIONAL JOURNAL OF SCIENTIFIC STUDY*, *4*(7), 140-143.

34. Shi, Q., Zhang, B., Huo, N., Cai, C., Liu, H., and Xu, J. (2016). Association between myocardial infarction and periodontitis: a meta-analysis of case-control studies. Frontiers in physiology, 7, 519.

35. Singh, A., Uthappa, S., Govindaraju, V., & Venkatesh, T. (2002). Serum markers for early diagnosis of non- 'Q'wave and 'Q'wave myocardial infarction. Indian Journal of Clinical Biochemistry, 17(1), 25-28.

36. Tibaut, M., Caprnda, M., Kubatka, P., Sinkovič, A., Valentova, V., Filipova, S., ... & Rodrigo, L. (2019). Markers of Atherosclerosis: Part 1–Serological Markers. Heart, Lung and Circulation, 28(5), 667-677.

37. Turk-Adawi, K., Sarrafzadegan, N., Fadhil, I., Taubert, K., Sadeghi, M., Wenger, N. K., ... and Grace, S. L. (2018). Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden. *Nature Reviews Cardiology*, *15* (2), 106.

38. Wennberg, P., Wensley, F., Di Angelantonio, E., Johansson, L., Boman, K., Rumley, A., ... & Jansson, J. H. (2012). Haemostatic and inflammatory markers are independently associated with myocardial infarction in men and women. Thrombosis research, 129(1), 68-73.

39. Wierer, M., Prestel, M., Schiller, H. B., Yan, G., Schaab, C., Azghandi, S., ... and Aherrahrou, Z. (2018). Compartment-resolved proteomic analysis of mouse aorta during atherosclerotic plaque formation reveals osteoclast-specific protein expression. Molecular and Cellular Proteomics, 17 (2), 321-334.

40. Yu, M., Tsai, S. F., and Kuo, Y. M. (2017). The therapeutic potential of anti-inflammatory exerkines in the treatment of atherosclerosis. International journal of molecular sciences, 18 (6), 1260.

41. Yao, H. C. *et al*, (2013). Correlation between serum high-mobility group box- 1 levels and high-sensitivity C-reactive protein and troponin I in patients with coronary artery disease. Experimental and therapeutic medicine, 6(1), 121-124.

42. Zhang, D., Li, F., Du, X., Zhang, X., Zhang, Z., Zhao, W., and Du, G. (2019). Diagnostic accuracy of biomarker D-dimer in patients after stroke suspected from venous thromboembolism: a diagnostic meta-analysis. Clinical biochemistry, 63, 126-134.

43. Zhu, Y., Xian, X., Wang, Z., Bi, Y., Chen, Q., Han, X., ... and Chen, R. (2018). Research progress on the relationship between atherosclerosis and inflammation. Biomolecules, 8 (3), 80.